Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of...

全面介紹

Na minha lista:
書目詳細資料
發表在:Case Rep Hematol
Main Authors: Abidi, Maheen Z., Haque, Javeria, Varma, Parvathi, Olteanu, Horatiu, Guru Murthy, Guru Subramanian, Dhakal, Binod, Hari, Parameswaran
格式: Artigo
語言:Inglês
出版: Hindawi Publishing Corporation 2016
主題:
Case Report
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC5097796/
https://ncbi.nlm.nih.gov/pubmed/27843657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2016/2389038
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍